IgG-RFBCSMPT-dgA consists of deglycosylated ricin A chain (dgA) coupled to the monoclonal antihuman CD22 antibody, RFB4. This study determined the maximally tolerated dose (MTD) of this immunotoxin (IT) administered as a continuous 8-day infusion to 18 patients with B-cell lymphoma (30% CD22+ tumor cells) over 8 days. The MTD was 19.2 mg/ m2/192 h (maximum toxicity grade l), with vascular leak syndrome (VLS) as dose-limiting toxicity (DLT) at 28.8 mg/ m2/192 h (grades 3 through 5 in 7 of 11 patients). Predictors of severe VLS included serum IT concentrations greater than 1.000 ng/mL and the absence of circulating tumor cells. Decreased urine sodium excreted in 24 hours provided evidence for mild VLS without notable changes in serum albumin. Four partial responses, 3 minor responses, 6 stable disease, and 3 progression of disease were observed. The mean maximal serum concentration (Cmax) in initial courses T ARGETED THERAPIES seek to minimize nonspecific effects of cancer treatment by delivering the toxic moiety to tumor cells via a carrier (antibody or ligand) with high affinity for tumor cells. One strategy uses poisons of plant or bacterial origin which inhibit protein synthesis, conjugated to antibodies directed against determinants selectively expressed on tumor cells (immunotoxins ITS]).'^^ Alternatively, chimeric molecules may be created by expressing toxin genes fused to genes encoding growth factors or engineered antibodie~.',~ These proteins bind to target cells by high-affinity receptors for the growth factor or molecules recognized by the antibody.
IgG-RFBCSMPT-dgA consists of deglycosylated ricin A chain (dgA) coupled to the monoclonal antihuman CD22 antibody, RFB4. This study determined the maximally tolerated dose (MTD) of this immunotoxin (IT) administered as a continuous 8-day infusion to 18 patients with B-cell lymphoma (30% CD22+ tumor cells) over 8 days. The MTD was 19.2 mg/ m2/192 h (maximum toxicity grade l), with vascular leak syndrome (VLS) as dose-limiting toxicity (DLT) at 28.8 mg/ m2/192 h (grades 3 through 5 in 7 of 11 patients). Predictors of severe VLS included serum IT concentrations greater than 1.000 ng/mL and the absence of circulating tumor cells. Decreased urine sodium excreted in 24 hours provided evidence for mild VLS without notable changes in serum albumin. Four partial responses, 3 minor responses, 6 stable disease, and 3 progression of disease were observed. The mean maximal serum concentration (Cmax) in initial courses T ARGETED THERAPIES seek to minimize nonspecific effects of cancer treatment by delivering the toxic moiety to tumor cells via a carrier (antibody or ligand) with high affinity for tumor cells. One strategy uses poisons of plant or bacterial origin which inhibit protein synthesis, conjugated to antibodies directed against determinants selectively expressed on tumor cells (immunotoxins ITS]).'^^ Alternatively, chimeric molecules may be created by expressing toxin genes fused to genes encoding growth factors or engineered antibodie~.',~ These proteins bind to target cells by high-affinity receptors for the growth factor or molecules recognized by the antibody.
IgG--4-SMPT-dgA was prepared by conjugating the IgG, murine monoclonal anti-CD22 antibody -4 to deglycosylated ricin A-chain (dgA) using the disulfide linker, SMPT.4.' The use of dgA avoids hepatic uptake of the IT, and SMPT confers stability in plasma. CD22 is expressed on tumor cells in 60% to 70% of patients with non-Hodgkin's lymphoma.6 IgG-RFBCSMPT-dgA has antitumor activity in SCID mice with human lymphoma xenografts.' In a phase I study using a dose regimen developed in the SCIDDaudi mouse model, IgG-RFEiCSMPT-dgA induced clinical responses in a population of heavily pretreated patients when administered as a 4-hour bolus infusion every 48 hours over a period of 8 days.' The dose-limiting toxicity (DLT) was vascular leak syndrome (VLS), manifested in its mildest form by hypoalbuminemia, but including more severe abnormalities including edema, weight gain, pulmonary infiltrates, and, in its most severe form, central nervous system (CNS) dysfunction, rhabdomyolysis, and renal failure. ' The current study was designed to determine whether the therapeutic index of IgG-RFBCSMPT-dgA would improve by administering the IT by continuous infusion with the goal of maintaining constant blood concentrations. Our results indicate that continuous infusion of this IT induces clinical responses at well-tolerated doses. The DLT was VLS, which occurred at a dose comparable to that observed when the same IT was administered by the bolus dose regimen. Our data suggest that there is a relationship between the occurrence of severe VLS and the serum concentration of IT achieved 3 to 4 days after initiation of the infusion. In addition, circulating tumor cells appear to protect against VLS.
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SAUSVILLE ET AL aggressive salvage approaches including bone marrow transplantation by virtue of patient preference or poor response to regimens intended to cause maximal cytoreduction. Concomitant administration of steroids was not permitted, and Chemotherapy was withheld for at least 2 weeks before initiation of treatment. Patients who had received prior radiation therapy must have demonstrated progression of disease in the radiation port or have evidence of active disease outside of any port. In addition, a cardiac ejection fraction of 35%, creatinine clearance of greater than 60 mL/min, and less than I pg/mL of human antimouse antibody (HAMA) or human antiricin antibody (HARA) were required for entry.
Pathology and eligibility. Biopsies were obtained for immunohistochemical analysis of CD22 expression using the RFB4 antibody according to standard protocols. Where open biopsy was not feasible, cytology specimens obtained by needle aspiration were evaluated for expression of CD22 using RFB4 by direct staining of fixed cells or by flow cytometry of cell suspensions.
Flow cytomerric analysis. Pretreatment and posttreatment circulating peripheral blood mononuclear cells were immunophenotyped by previously described methods? including use of phycoerythrinconjugated W B 4 (Dako, Carpinteria, CA).
IgG-RFB4-SMPT-dgA. IgG-RFB4-SMPT-dgA was prepared"' using dgA (Inland Laboratories, Austin, TX), the IgG,K murine monoclonal antibody RFB4 (Abbott Biotech, Needham, MA), and the SMPT crosslinker (Pierce, Rockford, IL). The study was approved under IND 2974 and the IRBs of the National Cancer Institute and the University of Texas Southwestern Medical School. Before treatment, all patients gave written informed consent.
Dosage and administration. The IT was intended for administration by continuous infusion over 8 days. Dose levels 1, 2, and 3 were 9.6, 19.2, and 28.8 mg/mz/192 h, respectively. These dose levels were chosen to give cumulative doses similar to those used in a prior study in which the same IT was infused as four bolus doses at 48-hour intervals over 8 days. 8 The administration of the IT was in all cases preceded on day 1 by a test dose of 0.2 mg by rapid intravenous (IV) push. The test dose was intended to rule out evidence of immediate hypersensitivity not predicted by prescreening for HAMAMARA. This dose was not included as part of a patient's total dose calculation.
Assessment of response. Patients were assessed for response between 3 and 4 weeks after completion of their initial course. A complete response (CR) was defined as disappearance of all disease for 1 month; a partial response (PR) was defined as greater than a 50% reduction in the volume of disease for at least I month, without worsening of individual lesions or new lesions; and a minor response (MR) was defined as a clear biologic effect of less than 50% reduction of tumor mass maintained for at least I month, or greater than a 50% reduction maintained for less than 1 month. Stable disease (SD) was defined as minimal change. Progression of disease (PD) signified a greater than 25% increase in summed tumor masses. Patients were eligible for retreatment if they achieved a CR, PR, or MR and had less than 1 pg/mL of HAMA or HARA at the time of re-treatment.
Assessment of toxicity. The NCI Common Toxicity criteria" were used. Vascular leak was specifically graded as follows: grade 1, minimal ankle pitting edema; grade 2, ankle pitting edema and weight gain, but total weight gain of less than 10 lb; grade 3, peripheral edema with a weight gain of greater than 10 lb or pleural effusion with no pulmonary function deficit documented; grade 4, anasarca, pleural effusion or ascites with pulmonary function deficit or pulmonary edema; and grade 5, respiratory failure requiring mechanical ventilation in the setting of pulmonary edema or hypotension requiring pressor support.
ITserum concentrations, HAMMHARA levels, and cytokine levels. IT concentrations were measured as described previously.'2 Initial pharmacokinetic parameters were obtained by noncompartmental methods using area under the curve (AUC) as calculated by the trapezoidal rule and extrapolating to infinity.I3 These parameters were refined by fitting of the data to a one compartment open-linear model using the Nelder-Mead iterative algorithmi4 as computed by ADAPT I1 (01992; Biomedical Simulations Resources, University of Southern California, Los Angeles, CA). Additional models were tested to compare fit to one and two compartment models, as well as to examine the possibility of nonlinear elimination. Model selection was determined by the Akaike's information criterion."
HAMA and HARA were determined as described previously." Serum cytokines and their receptors were determined by commercial enzyme-linked immunosorbent assay (ELISA) kits: interleukin-la (IL-la) and IL-4 from R+D Systems (Minneapolis, MN); IL-2 from Dupont-NEN Research Products (Boston, MA); soluble IL-2 receptors (sIL-2R) from T-cell Diagnostics (Cambridge, MA); IL-6, slL-6R, and IL-l0 from BioSource International (Camarillo, CA); and sELAM-I and SICAM-1 from Bender MedSystems (Vienna, Austria). Total serum nitratehitrite levels were determined in a 96-multiwell format by converting nitrates to nitrites using cadmium and reacting the product with a modification of the Greiss procedure."
RESULTS

Patients and pathology.
Eighteen patients were entered into this study ( Table l) . The median age was 60 years. Ten patients were male and 8 were female. All patients were originally diagnosed with a low-grade lymphoma, except in 1 case in which a retrospective review of slides showed lymphocyte-predominant Hodgkin's disease. Patients had received a mean of 3.8 prior courses of chemotherapy (range, 1 to 8) and 7 had at least 1 prior course of radiation therapy. Eight of 18 cases had evidence of transformation to a more aggressive histology at entry into the study. CD22 expression was determined using RFB4 (Table 2) . Immunohistochemical analyses in 13 patients indicated that greater than 50% of malignant cells expressed RFB4.
Clinical response and toxicity. Table 2 summarizes the clinical responses and toxicity during the first course of treatment. Of the 18 patients treated, 16 were considered evaluable for clinical response having received at least 3 days of continuous infusion and having survived for at least 4 weeks. Patient no. 9 received less than 24 hours of treatment since the initial course was complicated by atrial fibrillation soon after insertion of a central venous catheter. Staphylococcal bacteremia followed, presumably resulting from manipulation of the catheter, and the patient declined further treatment. Patient no. 18 died of complications related to VLS after receiving a 3-day infusion at dose level 3. At autopsy, unsuspected pulmonary parenchymal involvement with lymphoma was documented as well as marked heterogeneity of CD22 expression at different sampling sites. Lymphomatous infiltrates of the small bowel were CD22'. Neoplastic cells in a supraclavicular lymph node failed to express CD22, despite overt CD20 expression.
At 19.2 mg/m2/192 h (dose level 2), patient no. 6 achieved a PR after two courses of treatment maintained for 6 months, whereas patient no. 5 experienced an MR with an approximately 40% volumetrically determined decrease in the sum of node and spleen volumes maintained for 8 months.
At import was related to VLS, as has been described previously 
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1Urine volume (1) tBilirubin (1) TTransarninases ( with ITS containing blocked ricin," native,'* deglycosylated,R,'2 or recombinant" ricin A chain as well as Pseudomonas exotoxin*"-derived conjugates. The first two dose levels were very well tolerated, with only grade 1 or 2 toxicity ( Table 2 ). Significant toxicity became apparent at dose level 3. Of l 1 patients evaluable for toxicity, the initial courses of 4 patients (nos. 12, 15, 17, and 18) were not completed because of VLS during administration of the first course. In these four cases (Table 3) , hypotension (grade 3 in no. 12), pulmonary infiltrates, and oliguria (grade 4 in nos. 15 and 17 and grade 5 in no. 18, with death caused by refractory hypotension and respiratory failure) were apparent in the SAUSVILLE ET AL interrupted courses. Of the remaining 7 patients treated at dose level 3, 3 experienced grade 3 VLS, with weight gain and peripheral edema, although evidence of pulmonary parenchymal compromise was not evident, and symptomatic relief was obtained with diuretics.
Other adverse experiences described in Table 3 were generally either constitutional or unrelated to IT therapy, with the exception of transient expressive aphasia in patient no. 15 in the setting of florid pulmonary VLS with only prior transient hypotension. Aphasia gradually resolved over the course of several days. Radiographic and magnetic resonance imaging of the patient showed no structural basis in the CNS for the syndrome. Lumbar puncture at the time of the speech abnormality showed an opening pressure of 23 cm H20, 2 white blood cell (WBC)/pL, 1 red blood cell (RBC)/pL, protein at 115 mg/dL, and glucose at 88 mg/dL. Echocardiogram was without evidence of vegetations, and Doppler carotid studies showed only minimal evidence of carotid atherosclerotic disease.
HAMA and HARA responses. As shown in Table 4 , the appearance of greater than 1 pg/mL HAMA or HARA was delayed in several patients, so that at least 1 re-treatment of 6 of 7 responding patients (PR or MR) was possible. In 1 patient (no. IO), the presence of 4.8 pg/mL HARA precluded re-treatment despite evidence of an MR. Two patients received 2. 2 patients received 3, and 2 patients received 5 courses of therapy. Ultimately, 12 of 16 (75%) of evaluable patients developed HAMA or HARA.
Correlations of toxicity und pharmacology. Table 5 shows that 8 evaluable patients had evidence of circulating tumor cells as determined by flow cytometry; in 3 patients (nos. 7, IO, and 1 l), the number of circulating tumor cells For The number in the parenthesis indicates the maximal toxicity grade experienced by the patient during the infusion from which the pharmacoki-
Abbreviations: L a x , peak serum concentration (nglmL); TIE, elimination half-life (h); Vd, volume of distribution (L); AUC, area under the netic parameters were estimated. concentration versus time curve (mg. h/L); Cl, clearance (Uh).
was greater than 1 , OOO cells/pm. Table 5 also presents pharmacokinetic parameters for the initial infusion. Comparing dose levels 1 and 2 (9.6 and 19.2 mg/m2/192 h, respectively), maximal serum concentrations achieved during the 8-day infusion (C,,,=) increased incrementally (75 t 16 ng/mL and 443 +-144 ng/rnL, mean +-SD, respectively), with a relatively small interpatient variability (CVs of 21% and 33%, respectively). However, at dose level 3 (28.8 mg/m2/192 h) there was considerable variability in the pharmacokinetic profile (eg, C, = 9.6 ng/mL for patient no. 10 and 2,032 ng/mL for patient no. 15). The mean C,,, 2 SD for patients treated at dose level 3 was 1,102 5 702 ng/mL, but with a CV of 64%.
Peak serum concentrations of less than 1,300 ng/rnL were observed in patients no. 2, 6, 7, 10, 11, 13, 14, and 16; in these patients, the clearance (Cl) was relatively rapid (7.9 2 17.6 L/h, mean 5 SD) and the half-life was relatively short (8. Pharmacokinetic parameters of the IT were examined in all 17 evaluable patients undergoing a total of 26 treatment courses (Fig 1) . IT elimination data fit best to a one-compartment model, although there were 3 patients for whom a twocompartment model provided a better fit; these 3 patients had evidence of circulating tumor cells. There was no evidence of decreased clearance with increasing dose. There was an inverse correlation between the elimination constant (k) and the area under the concentration versus time curve (AUC) and between the Vd and C, , (Fig 1A and B, respectively) . Despite these correlations, it is important to emphasize that there were large interpatient and intrapatient variations in the pharmacokinetic parameters (the CV for k, was 70.3%; for v& 325%; and for cl, 298%). One patient (no. 5) had a 215% increase in C, , from one course to the next, whereas another (no. 7) had a 483% decrease from one course to the next. Furthermore, patient no. 10 had an AUC of 1.2 mg h L compared with patient no. 11, who received the same dose as no. 10 and yet had an AUC of 165 mg -N L .
Semm (IT) and toxicity. Pharmacokinetic parameters presented in Table 5 trations of IT than patients with grade 3 VLS, whereas the highest serum concentrations (> 1,000 ng/mL) of IT were observed in those patients with grade 4 or 5 VLS. In contrast, those patients with a day 3 IT concentration of less than 1,000 ng/mL tended to have less than grade 3 toxicity. Patients with less than 750 ng/mL on day 4 only had grade l or 2 VLS. Statistical comparisons of toxicity with respect to IT concentration achieved on each day of treatment were SAUSVILLE ET AL made using the Kruskal-Wallis test. Two-tailed P values for comparisons of IT concentrations associated with grades 1 or 2 versus grade 3 versus grade 4 toxicity are as follows: on day 2. P = ,020; on day 3, P = ,026; and on day 4, P = .04. Figure 3A shows the duration of infusions administered at dose level 3 that were interrupted because of the occurrence of grade 3 to 5 VLS. These patients were all female and infusions were interrupted between 60 and 96 hours after the initiation of treatment. In all 4 cases, at the time of interruption, serum concentrations of IT were greater than 1,000 ng/mL (Fig 3B) , yet notable decreases in albumin did not precede the occurrence of severe VLS (Fig 3C) . In 1 case, the patient's serum albumin levels were unchanged. Thus, it appears that serious VLS manifested as a pulmonary compromise or hypotension is not necessarily preceded by hypoalbuminemia.
The well-tolerated doses of IT at levels 1 and 2 were not accompanied by large decreases in serum albumin (data not shown). However, 24-hour levels of urine sodium excretion underwent a notable decrease during IT therapy, without intentional sodium or fluid restriction (Fig 4A and B) . Unfortunately, the clinical deterioration that occurred in patients with interrupted infusions (Fig 3A) often prompted the administration of exogenous fluids or the unreliable collection of specimens as the patient was moved to an intensive care setting. Hence, clear correlations between urine sodium excretion and the development of severe VLS were not possible. These data support the possibility that there is heterogeneity in the disposition of this IT by different patients, resulting in variations in serum IT concentrations, with predictable susceptibility to the development of VLS as a function of exposure to concentrations greater than 1,000 ng/mL early in the course of the infusion. Decreases in serum albumin did not invariably precede the development of severe VLS and, in fact, mild VLS, as manifested in patients at dose levels 1 and 2 (Fig 4) , occurred along with decreased urinary sodium excretion before the occurrence of hypoalbuminemia. Cytokines and nitrates. No significant elevations or changes in the concentrations of serum IL-la, IL-2, IL-4, IL-6, or IL-10 were detected during treatment. sELAM and SICAM-l were detected in all patients, but differences in concentrations did not correlate with either VLS or clinical response. Basal serum nitrate levels varied from 14 to 143 pmol/L. Changes in nitrate levels did not correlate with toxicity; the 4 patients with grade 3 toxicity had changes in nitrates ranging from +9 to +94 prnol/L, but the 2 patients 3463 with grade 4 toxicity had changes in nitrate levels of + l 5 and -82 pmol/L, respectively. The patient with grade 5 toxicity had a change in nitrates of -26 pmoVL. Serum p2-microglobulin levels also did not change during the course of IT administration (data not shown).
Subsets of the patient population demonstrated alterations (absolute changes of >25% of the initial value) in the concentrations of serum sIL-2Rs during the course of treatment. Four patients (nos. l, 8, 14, and 16 ) experienced progressive decreases in levels of sIL-~Rs, and 3 of these achieved PRs. Transient increases in levels of sIL-2Rs were observed at one or more monitored time points in patients no. 5 , 7, 10, 12, 13, and 18, 3 of whom experienced an MR. Levels of sILdRs declined during the course of IT administration in 10 patients, increased in 4, and remained stable or undetectable in 3. Decreases in sIL-6Rs did not correlate with either response or toxicity.
DISCUSSION
The following major conclusions emerge from our study. First, there is a clear correlation between the development of serious toxicity and the serum concentration of IT achieved early in the infusion; patients whose serum concentrations of IT were less than 1,000 ng/mL throughout the course of the therapy had the least toxicity, whereas those with greater than 1,000 n g h L by day 3 were at increased Our data and those in a previous report using the same IT8 lead us to suggest that the conventional definition of MTD is relatively meaningless when applied to this and perhaps related ITS (at least in patients with indolent lymphomas). Thus, had this trial included only patients with large numbers of circulating tumor cells, a higher MTD could have emerged. Conversely, if all patients lacked circulating tumor cells, the MTD could have been lower, although it is clear that patients both with (eg, patient no. 6) and without (eg, patient no. 5) circulating tumor cells tolerate our proposed MTD with easily manageable toxicity. More pertinently, all patients with sustained serum concentrations of IT up to 1,000 ng/mL (irrespective of the administered dose level) tolerated the IT with readily reversible toxicity and with evidence of clinical response in some patients. This result suggests that, rather than using empiric doses, a regimen that produces sustained concentrations of serum IT (eg, between 500 to 1,000 ng/mL) should be devised.
Other investigators have noted comparable serum concentrations of IT at their respective MTDs as well as variability in IT levels in patients with circulating tumor cells. For example, Grossbard et all7 used a bolus dose regimen to administer anti-CD19-blocked ricin (molecular weight [M,] approximately 2.15 X lo5 compared with M, approximately 1.87 X 10' for the IT used here). They observed IT concentrations of approximately 215 to 600 ng/mL at their MTD, at which 24 of 25 patients developed hypoalbuminemia. In another trial with the blocked ricin. but administered as a 7-day continuous infusion, a steady-state concentration at the MTD of approximately 1 . l 6 n m o m o r 269 ng/mL was achieved." These investigators also noted very low levels of their ITS in patients with either chronic lymphocytic leukemia (CLL) or acute lymphocytic leukemia (ALL). In patients receiving the same regimen after autologous bone marrow transplants, blocked ricin concentrations of 600 ng/mL were safe. but the MTD was lower than that achieved in an analogous trial in patients with bulky disease." Using an IT structurally analogous to the one used here, Weiner et al" observed peak concentrations of 200 to 850 ng/mL at their MTD.
Compared with a previous trial8 with IgG-RFB4-SMPTdgA administered as an intermittent bolus schedule, peak serum concentration in the current trial again did not correlate with the administered dose, and the presence of lymphoma cells in the peripheral blood was associated with decreased toxicity. RFB4 has also been used as an Fab' construct in a phase I trial.'' Although the was markedly shorter, as expected for the smaller molecule, again there was notable interpatient variability in the handling of the IT, with, for example, a fivefold to sevenfold variation in peak concentrations achieved at the two highest dose levels studied. Thus, the variable handling of RFB4-derived ITS was not unique to the current patient population or dose schedule.
The most likely mechanism for VLS in these patients is that ITS directly damage vascular endothelial cells at high serum concentrations and relatively rapid increase of IT concentration to greater than 1,000 ng/mL in the first 3 days is a predictor of severe endothelial cell damage leading to serious VLS with hypotension and pulmonary compromise. Evidence for nontargeted toxicity of ITS to vascular endothelial cells in vitro has recently been reported.'' Before overt VLS, there may be a decrease in effective circulating volume, with the induction of a sodium-retaining state and a decrease in urinary Na output observed in our patients even at welltolerated dose levels I and 2. Maneuvers to reverse the damaging effects of this and perhaps other ITS to the vascular endothelium might reverse renal sodium retention as a sign of their efficacy.
Used as a single agent, the current trial has defined a range of serum IT concentrations that are well tolerated. A rapid assay to monitor IT concentrations would allow dose modifications to be made during the course of a continuous infusion. If the targeted serum concentration is between 500 and 1,000 ng/mL, we would predict good tolerance of the agent for at least the first 8 days. This concentration exceeds that associated with significant cell killing in vitro. Alternatively, a test dose with pharmacokinetic monitoring of IT concentrations could define a dose to yield this result. Recent studies have shown that administration of this IgG-RFB4-SMPTdgA in conjunction with another IT, an unarmed monoclonal or chemotherapy" has major biologic effects with some cures in the SCIDDaudi mouse model. Administration after maximal debulking of tumor may decrease the variability of serum concentrations, reduce toxicity, and improve cellular uptake of the IT. The studies presented here define a range of safe concentrations of IgG-RFBCSMPTdgA with evidence of biologic effects in patients with as well as those without detectable circulating tumor cells. 
